



Francisco Abad-Santos, MD, PhD

Professor, Pharmacology Department, Universidad Autónoma de Madrid
Clinical Pharmacology Department, Hospital Universitario de la Princesa
Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain
email: francisco.abad@salud.madrid.org / francisco.abad@uam.es

Research interests:

1. Clinical trials in healthy subjects and patients
2. Evaluation of bioavailability and bioequivalence
3. Pharmacogenetics of metabolizing enzymes, transporters and receptors

Our research group in the Hospital Universitario de la Princesa is dedicated to two research lines: clinical trials and pharmacogenetics.

We mainly perform phase I clinical trials, both in healthy subjects and in patients, but also phase II, III and IV studies in collaboration with other hospital researchers. We have extensive experience in studies of bioavailability and bioequivalence, where we can take care of the complete development. In addition, we take care of all the necessary procedures to conduct the clinical trials according to the standards of good clinical practice to ensure that the rights of the participating subjects are respected and that the data are reliable: management, monitoring and pharmacovigilance.

On the other hand, we carry out pharmacogenetic studies to identify polymorphisms that can alter the pharmacokinetics, pharmacodynamics and safety of different drugs. We have mainly worked with antipsychotics, antidepressants, analgesics, antiplatelets, anticoagulants, antineoplastic, antivirals and drugs for the treatment of psoriasis. We can also perform epigenetic studies and determination of drug concentrations in blood.

In clinical trials and translational research studies we have collaborated with other hospital specialists such as Dermatology, Psychiatry, Anesthesiology, Neurology, Neurosurgery, General Surgery, Emergency, Radiology, Hematology, Oncology, Pneumology, Rehabilitation, Neurophysiology, Ophthalmology, Pain Unit, Intensive Medicine, Endocrinology, Gastroenterology and Internal Medicine.

Selection of publications

1. Koller D, Belmonte C, Lubomirov R, Saiz-Rodríguez M, Zubiaur P, Román M, Ochoa D, Carcas A, Wojnicz A, **Abad-Santos F**. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. **J Psychopharmacol**. 2018; 32: 1212-1222.
2. González-Rojano E, **Abad-Santos F**, Ochoa D, Román M, Marcotegui J, Álvarez C, Gordon J, García-Arieta A. Evaluation of sex-by-formulation interaction in bioequivalence studies of efavirenz tablets. **Br J Clin Pharmacol**. 2018; 84: 1729-1737.
3. Saiz-Rodríguez M, Romero-Palacián D, Villalobos-Vilda C, Caniego JL, Belmonte C, Koller D, Bárcena E, Talegón M, **Abad-Santos F**. Influence of CYP2C19 phenotype on the effect of clopidogrel in patients undergoing percutaneous neurointervention procedure. **Clin Pharmacol Ther** 2018 Mar 14. doi: 10.1002/cpt.1067. [Epub ahead of print]
4. Ovejero-Benito MC, Cabaleiro T, Sanz-García A, Llamas-Velasco M, Rodríguez MS, Prieto-Pérez R, Talegón M, Román M, Ochoa D, Reolid A, Daudén E, **Abad-Santos F**. Epigenetic biomarkers associated with anti-TNF drugs response in moderate-to-severe psoriasis. **Br J Dermatol**. 2018; 178: 798-800.
5. Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, Baniandrés O, López-Estebanz JL, de la Cueva P, Daudén E, **Abad-Santos F**. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. **Pharmacogenomics J**. 2018; 18: 70-75.
6. Wojnicz A, Cabaleiro-Ocampo T, Román-Martínez M, Ochoa-Mazarro D, **Abad-Santos F**, Ruiz-Nuño A. A simple assay for the simultaneous determination of human plasma albendazole and albendazole sulfoxide levels by high performance liquid chromatography in tandem mass spectrometry with solid-phase extraction. **Clin Chim Acta**. 2013; 426: 58-63.

7. Cabaleiro T, Román M, Ochoa D, Tategón M, Prieto-Pérez R, Wojnicz A, López-Rodríguez R, Novalbos J, **Abad-Santos F**. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. **Drug Metab Dispos**. 2013; 41: 224-229.
8. Novalbos J, López-Rodríguez R, Roman R, Gallego-Sandín S, Ochoa D, **Abad-Santos F**. Effects of CYP2D6 genotype on the pharmacokinetics and safety of risperidone in healthy volunteers. **J Clin Psychopharmacol** 2010; 30: 504-511.
9. Rümke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, **Abad-Santos F**, von Sonnenburg F, Dramé M, Sängler R, Ballou WR. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. **Vaccine**. 2008; 26: 2378-2388.
10. Gálvez-Múgica MA, Santos-Ampuero MA, Novalbos J, Gallego Sandín S, Galiano A, Gilsanz F, García AG, **Abad-Santos F**. Ulnar nerve block induced by the new local anesthetic IQB-9302 in healthy volunteers: a comparison with bupivacaine. **Anesth Analg** 2001; 93: 1316-1320.